Comparative effectiveness study of group cognitive-behavioral therapy and of selective serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: a pragmatical clinical trial

Introdução: A Terapia Cognitivo-Comportamental (TCC) e os inibidores seletivos de recaptação de serotonina (ISRS) são considerados os tratamentos de primeira linha para o Transtorno Obsessivo-Compulsivo (TOC) nos ensaios clínicos randomizados (ECR). No entanto, a maior parte destes estudos exclui grande parte dos pacientes (em torno de 50%) por apresentarem comorbidades psiquiátricas. Ensaios clínicos pragmáticos e de efetividade, que costumam simular ambientes clínicos naturalísticos ao estudar amostras que representam melhor a população real comparando tratamentos ativos, são de grande importância para as decisões tomadas por um sistema de saúde e poucos têm sido feitos para avaliar a efetividade dos tratamentos para o TOC. O objetivo do presente estudo foi comparar os tratamentos de primeira linha para o TOC em uma amostra mais próxima da população que procura atendimento e avaliar características clínicas associadas às respostas aos tratamentos. Metodologia: Pacientes de 18 a 65 anos de idade, com escore de linha de base da YBOCS de pelo menos 16 para obsessões e compulsões, ou pelo menos 10 apenas para obsessões ou compulsões e com possíveis comorbidades psiquiátricas adicionais foram alocados seqüencialmente para tratamento de TCC em grupo (TCCG; n = 70) ou para tratamento medicamentoso (ISRS; n = 88). A TCCG consistiu em doze sessões semanais de duas horas cada com grupos de 6 a 8 pacientes, baseadas em um manual validado (Cordioli, 2002). O medicamento utilizado foi a fluoxetina com dosagem máxima de 80mg/dia. Foram analisadas respostas aos tratamentos como variáveis contínua (redução percentual na YBOCS) e categórica (redução de pelo menos 35% na YBOCS e ICG 1 muito melhor ou 2 melhor. Resultados: Os escores da YBOCS reduziram 23,13% no grupo tratado com TCCG e 21,54% no grupo tratado com ISRS, sem diferença estatística entre os grupos de tratamento (p = 0,875). Foi encontrada em 33,3% dos pacientes de TCCG e 27,7% dos pacientes de ISRS a redução de pelo menos 35% no escore da YBOCS e resposta à ICG 1 ou 2 (p = 0,463). O número médio de comorbidades psiquiátricas por paciente foi 2,7; e 81,4% da amostra apresentou pelo menos uma comorbidade. A redução na YBOCS foi significativamente menor entre os pacientes com uma ou mais comorbidade psiquiátrica (21,15% e 18,73%, respectivamente) do que entre os pacientes com TOC puro (34,62%) (p = 0,034). Sexo masculino, apresentar um escore inicial mais alto na Beck-A, ter abandonado o tratamento e apresentar comorbidade com Transtorno Depressivo Maior ou Distimia foram associados com taxas mais baixas de resposta ao tratamento, independente do tratamento recebido. Os resultados sugeriram que em uma população mais heterogênea os tratamentos de primeira linha para o TOC são menos efetivos. É necessário o desenvolvimento de intervenções que sejam efetivas para uma população da prática clínicaIntroduction: Cognitive-Behavioral Therapy (CBT) and selective serotonin reuptake inhibitors (SSRI) are considered the first line treatments for Obsessive-Compulsive Disorder (OCD) in randomized controlled trials (RCT). However, most of these trials exclude a great amount of patients (around 50%) for presenting psychiatric comorbidities. Pragmatical and effectiveness clinical trials simulate natural clinical environments and compare active treatments in samples that represent the real population. These trials are of great importance for decision makers of the health public system, and only a few trials have investigated the effectiveness of treatments to OCD. The aim of this study was to compare the first line OCD treatments in a sample closer to the OCD real population, and to evaluate clinical characteristics associated to responses to treatments. Methodoly: Patients (1865 years; baseline Yale-Brown Obsessive-Compulsive Scale (YBOCS) scores 16; potentially presenting additional psychiatric comorbidities) were sequentially allocated for treatment with group CBT (GCBT; n=70) or pharmacological treatment (SSRI; n=88). GCBT consisted in twelve two hours weekly sessions with groups of 6 to 8 patients, based in a validated manual (Cordioli, 2002). Medication utilized in SSRI group was fluoxetine, 80mg/day. Response to treatment was analyzed as continuous variable (percent reduction on YBOCS) and as categorical variable (reduction of at least 35% on YBOCS and CGI 1 much better or 2 better. Results: Mean Y-BOCS scores fell by 23.13% in the GCBT and 21.54% in the SSRI group. Symptom reduction did not differ between groups (p = 0.875). A reduction of at least 35% in baseline Y-BOCS score and a CGI rating of 1 (much better) or 2 (better) was achieved by 33.3% of patients in the GCBT and 27.7% in the SSRI group (p=0.463). Patients presented 2.7 mean number of psychiatric comorbidity, and 81.4% showed at least one additional disorder. The YBOCS reduction was significantly lower in patients with one or more psychiatric comorbidities (21.15%, and 18.73%, respectively) than those with pure OCD (34.62%) (p = 0.034). Low responses to treatments were found to be associated to: being male, presenting a high initial Beck-A score, comorbid major depression, dysthymia and abandoning treatment, independently of the treatment received. The development of effective interventions to a real population is necessar

Rabies transmitted by vampire bats to humans: An emerging zoonotic disease in Latin America? Revista Panamericana Salud Pública

Human rabies transmitted by vampire bats reached new heights in Latin America in 2005. A total of 55 human cases were reported in several outbreaks, 41 of them in the Amazon region of Brazil. Peru and Brazil had the highest number of reported cases from 1975 to 2006. In Peru, outbreaks involving more than 20 cases of bat-transmitted human rabies were reported during the 1980s and 1990s. During this period, a smaller number of cases were reported from outbreaks in Brazil. A comparison of data from field studies conducted in Brazil in 2005 with those from the previous decade suggests similar bat-bite situations at the local level. The objective of this study was to review the epidemiological situation and, on the basis of this information, discuss possible factors associated with the outbreaks. Prevention and control measures already recommended for dealing with this problem are also reviewed, and some further suggestions are provided

Rabies transmitted by vampire bats to humans: An emerging zoonotic disease in Latin America? Revista Panamericana Salud Pública

Human rabies transmitted by vampire bats reached new heights in Latin America in 2005. A total of 55 human cases were reported in several outbreaks, 41 of them in the Amazon region of Brazil. Peru and Brazil had the highest number of reported cases from 1975 to 2006. In Peru, outbreaks involving more than 20 cases of bat-transmitted human rabies were reported during the 1980s and 1990s. During this period, a smaller number of cases were reported from outbreaks in Brazil. A comparison of data from field studies conducted in Brazil in 2005 with those from the previous decade suggests similar bat-bite situations at the local level. The objective of this study was to review the epidemiological situation and, on the basis of this information, discuss possible factors associated with the outbreaks. Prevention and control measures already recommended for dealing with this problem are also reviewed, and some further suggestions are provided

Rabies transmitted by vampire bats to humans: An emerging zoonotic disease in Latin America? Revista Panamericana Salud Pública

Human rabies transmitted by vampire bats reached new heights in Latin America in 2005. A total of 55 human cases were reported in several outbreaks, 41 of them in the Amazon region of Brazil. Peru and Brazil had the highest number of reported cases from 1975 to 2006. In Peru, outbreaks involving more than 20 cases of bat-transmitted human rabies were reported during the 1980s and 1990s. During this period, a smaller number of cases were reported from outbreaks in Brazil. A comparison of data from field studies conducted in Brazil in 2005 with those from the previous decade suggests similar bat-bite situations at the local level. The objective of this study was to review the epidemiological situation and, on the basis of this information, discuss possible factors associated with the outbreaks. Prevention and control measures already recommended for dealing with this problem are also reviewed, and some further suggestions are provided

Rabies transmitted by vampire bats to humans: An emerging zoonotic disease in Latin America?

Human rabies transmitted by vampire bats reached new heights in Latin America in 2005. A total of 55 human cases were reported in several outbreaks, 41 of them in the Amazon region of Brazil. Peru and Brazil had the highest number of reported cases from 1975 to 2006. In Peru, outbreaks involving more than 20 cases of bat-transmitted human rabies were reported during the 1980s and 1990s. During this period, a smaller number of cases were reported from outbreaks in Brazil. A comparison of data from field studies conducted in Brazil in 2005 with those from the previous decade suggests similar bat-bite situations at the local level. The objective of this study was to review the epidemiological situation and, on the basis of this information, discuss possible factors associated with the outbreaks. Prevention and control measures already recommended for dealing with this problem are also reviewed, and some further suggestions are provided

The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder

Few case series studies have addressed the issue of treatment response in patients with obsessive-compulsive disorder (OCD) and comorbid post-traumatic stress disorder (PTSD), and there are no prospective studies addressing response to conventional treatment in OCD patients with a history of trauma (HT). the present study aimed to investigate, prospectively, the impact of HT or PTSD on two systematic, first-line treatments for OCD. Two hundred and nineteen non-treatment-resistant OCD outpatients were treated with either group cognitive-behavioral therapy (GCBT n = 147) or monotherapy with a selective serotonin reuptake inhibitor (SSRI n = 72). Presence of HT and PTSD were assessed at intake, as part of a broader clinical and demographical baseline characterization of the sample. Severity and types of OCD symptoms were assessed with the Yale-Brown Obsessive-Compulsive Scale (YBOCS) and the Dimensional YBOCS (DYBOCS), respectively. Depression and anxiety symptoms were measured with the Beck Depression Inventory (BDI) and the Beck Anxiety Inventory (BAI). Both treatments had 12-week duration. Treatment response was considered as a categorical [35% or greater reduction in baseline YBOCS scores plus a Clinical Global Impression-Improvement rating of better (2) or much better (1)] and continuous variable (absolute number reduction in baseline YBOCS scores). Treatment response was compared between the OCD + HT group versus the OCD without HT group and between the OCD + PTSD group versus the OCD without PTSD group. Parametric and non-parametric tests were used when indicated. Data on HT and PTSD were available for 215 subjects. Thirty-eight subjects (17.67% of the whole sample) had a positive HT (OCD + HT group) and 22 subjects (57.89% of the OCD + HT group and 10.23% of the whole sample) met full DSM-IV criteria for PTSD. the OCD + HT and OCD without HT groups presented similar response to GCBT (60% of responders in the first group and 63% of responders in the second group, p = 1.00). Regarding SSRI treatment, the difference between the response of the OCD + HT (47.4%) and OCD without HT (22.2%) groups was marginally significant (p = 0.07). in addition, the OCD + PTSD group presented a greater treatment response than the OCD without PTSD group when treatment response was considered as a continuous variable (p = 0.01). the age when the first trauma occurred had no impact on treatment response. in terms of specific OCD symptom dimensions, as measured by the DYBOCS, OCD treatment fostered greater reductions for the OCD + PTSD group than for the OCD without PTSD group in the scores of contamination obsessions and cleaning compulsions, collecting and hoarding and miscellaneous obsessions and related compulsions (including illness concerns and mental rituals, among others). the OCD + PTSD group also presented a greater reduction in anxiety scores than the OCD without PTSD group (p = 0.003). the presence of HT or PTSD was not related to a poorer treatment response in this sample of non-treatment-resistant OCD patients. Unexpectedly, OCD patients with PTSD presented a greater magnitude of response when compared with OCD without PTSD patients in specific OCD symptom dimensions. Future studies are needed to clarify if trauma and PTSD have a more significant impact on the onset and clinical expression of OCD than on the conventional treatment for this condition, and whether OCD stemming from trauma would constitute a subtype of OCD with a distinct response to conventional treatment.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Univ São Paulo, Dept & Inst Psychiat, Sch Med, BR-05403010 São Paulo, BrazilUniv São Paulo, Inst Math & Stat, BR-05403010 São Paulo, BrazilUniv Fed Rio Grande do Sul, Dept Psychiat & Forens Med, BR-90035903 Porto Alegre, RS, BrazilUniversidade Federal de São Paulo, Dept Psychiat, BR-04026001 São Paulo, BrazilUniversidade Federal de São Paulo, Dept Psychiat, BR-04026001 São Paulo, BrazilFAPESP: 06/61459-7FAPESP: 06/50273-0FAPESP: 06/50829-8FAPESP: 2005-55628-8CNPq: 420.122/2005-2Web of Scienc

Perfectionism and sensory phenomena: phenotypic components of obsessive-compulsive disorder

Background: The aim of the study was to investigate how perfectionism and sensory phenomena (SP) interact as possible phenotypic components of obsessive-compulsive disorder (OCD). Methods: Forty-seven adult outpatients, meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria for OCD, and a control group of 41 community subjects were assessed using the Frost Multidimensional Perfectionism Scale (FM PS), the University of Sao Paulo-Sensory Phenomena Scale, and other standard measures of OCD severity. Results: Three of the FMPS subscales (""concern over mistakes,"" ""doubts about action,"" and ""parental criticism"") were significantly different between OCD patients and control subjects. All subtypes of SP were significantly more frequent and more severe in OCD than in control subjects. The ""incompleteness"" subtype of SP was associated with high scores on all dimensions of the FMPS, whereas the ""just-right"" subtype of SP was only associated with ""doubts about action,"" ""personal standards,"" and ""organization"" subscales of the FMPS. Conclusions: Presence and severity of SP and specific elements of perfectionism clearly distinguish OCD patients from healthy control subjects. Some SP subtypes are associated with specific FPMS subscale scores, whereas others are not. These results emphasize the relevance of assessing different subtypes of perfectionism and SP in OCD patients as important subcomponents of the OCD phenotype. (C) 2009 Elsevier Inc. All rights reserved.Downs International Health Student Travel Fellowship, Yale University (JCL)FAPESP Foundation for the Support of Research in the State of Sao Paulo[1999/08560-6]FAPESP Foundation for the Support of Research in the State of Sao Paulo[1998/15013-9]FAPESP Foundation for the Support of Research in the State of Sao Paulo[2003/07451-6]FAPESP Foundation for the Support of Research in the State of Sao Paulo[2005/55628-8]CNPq Brazilian Council for Scientific and Technological Development[521369/96-7]CNPq Brazilian Council for Scientific and Technological Development[133339/2004-1]National Institute of Mental Health (NIH)[K05MH076273

Therapeutic comparison between treatments for Vulvar Lichen Sclerosus: study protocol of a randomized prospective and controlled trial

Abstract Background Vulvar lichen sclerosus (VLS) is a lymphocyte-mediated disease of unknown etiology that can cause intense itching as well stenosis, hindering the evacuation and urination. It can also limit the sex life due to severe local pruritus, pain and dyspareunia (pain during sexual intercourse). The standard treatment for this disease is the use of topical corticosteroids to reduce the clinical symptoms and to try to increase disease-free intervals. Photodynamic therapy (PDT), a treatment that associates a light radiation with a photosensitizing agent and photobiomodulation (PBM) are therapies that can promote effective immunomodulatory responses at the application site by means of photophysical and photochemical phenomena from the molecular to the systemic level, which promote their use in chronic dermatoses. The aim is to compare the effects of PDT, PBM, and topical corticosteroid in VLS evaluating clinical, histological, immunohistochemical and spectroscopic responses. Methods The study is prospective, randomized and controlled, in a population of 60 women with histological diagnoses of VLS. There will be 3 treatments groups: PDT, PBM and topical corticosteroid (control group), where will be allocated by randomization 20 patients in each one. The clinical course will be monitored by measuring local temperature, itching, atrophy, and the area of the lesion. Histologically, the slides will be classified and will have the ordering of collagen fibers quantified. Immunohistochemical analysis will be done using the markers IFN-γ, TGF-β, CD4, CD8, IL-1, p53 and Ki-67. Finally, the spectroscopic evaluation will be done by reflectance. Descriptive and inferential statistical analyses will be conducted to compare the groups and make associations between different responses. The study is an open-label for patients with active symptomatic disease with a period of 1 year follow-up to determine the rate of recurrence in each groups. Discussion The immunological effects of PDT and PBM are described by several authors in inflammatory skin diseases, stimulating the production and organization of the associated collagen. Thus, it is reasonable to determine the efficacy and safety of these new treatments in VLS, in comparison to the control group, analyzing the recurrence time, the impact on the optical properties of the skin, and the benefit to patients. Trial Registration ClinicalTrials.gov: NCT02416531